Posted on Leave a comment

Diabetes Linked to 47% Increased Colorectal Cancer Risk in Low-Income African American Population

New Study Highlights Urgency of Screening for Individuals with Diabetes

In a groundbreaking cohort study involving 54,597 adults from a predominantly African American, low-income population, researchers have unveiled a concerning link between Type 2 diabetes and an elevated risk of colorectal cancer (CRC). The study, conducted by the Southern Community Cohort Study in the US, discovered that individuals with a diabetes diagnosis faced a staggering 47% increased risk of developing CRC compared to those without diabetes.

The association between diabetes and CRC risk was particularly pronounced in participants without recent colonoscopy screenings and those with more recent diabetes diagnoses. The findings underscore the crucial role of timely and regular colonoscopies in mitigating the heightened risk associated with diabetes.

Key Findings:

  • Diabetes diagnosis associated with a 47% increased risk of developing CRC.
  • Stronger association observed in participants without recent colonoscopy screenings.
  • Participants with a more recent diabetes diagnosis faced a greater CRC risk.

Implications and Recommendations: The study’s lead researcher emphasized the importance of these findings, suggesting that the emerging association between diabetes and elevated CRC risk highlights the critical need for screening, especially through colonoscopies, for individuals with diabetes. The research implies that proactive measures such as regular screenings can potentially disrupt the adverse effects of diabetes-related metabolic dysregulation, reducing CRC disparities in vulnerable populations.

Public Health Message: As diabetes continues to affect millions worldwide, the study urges a heightened focus on prevention and control to curb the growing CRC disparities. The results emphasize the potential life-saving impact of routine colonoscopies for individuals with diabetes, underscoring the need for accessible and timely healthcare interventions.

The study’s insights could inform public health strategies, emphasizing the integration of diabetes management and colorectal cancer screening programs, particularly in communities facing socioeconomic challenges. Ultimately, the research sheds light on a critical intersection of health concerns, urging a comprehensive approach to safeguard the well-being of vulnerable populations.

Credit: JAMA Network Open Journal

Posted on Leave a comment

Low Diagnostic Testing Rates Among Younger Veterans with Iron-Deficiency Anemia and Hematochezia May Contribute to Colorectal Cancer Disparities

A recent study conducted within the Veterans Health Administration (VHA) between 1999 and 2019 revealed concerning findings about diagnostic testing rates and disparities in follow-up for younger veterans with iron-deficiency anemia (IDA) and/or hematochezia. The study, which focused on individuals aged 18 to 49 years, aimed to evaluate the time to diagnostic testing among these patients.

The key findings of the study include:

Low Diagnostic Testing Rates: The study found that diagnostic testing rates for veterans with IDA were 22% at 2 years, and for those with hematochezia, the rate was slightly higher at 40%. This suggests that a significant portion of younger veterans with these symptoms did not undergo recommended diagnostic tests within a reasonable timeframe.

Sex-Based Disparities: Female veterans with IDA were significantly less likely to complete diagnostic testing compared to their male counterparts. This disparity raises questions about why women with IDA may not be receiving the recommended follow-up.

Race and Ethnicity Disparities: The study also highlighted disparities based on race and ethnicity. Black veterans with IDA and Hispanic veterans with IDA and/or hematochezia were less likely to receive diagnostic testing compared to White veterans. These disparities could be a contributing factor to variations in colorectal cancer outcomes among different racial and ethnic groups.

Age and Geographic Region: The likelihood of diagnostic testing completion increased with age, with older veterans being more likely to undergo the recommended tests. The region of care within the VHA also had an impact on diagnostic test completion.

Colorectal cancer is a significant health concern, and early detection and timely diagnostic testing are crucial for improving outcomes. The study’s findings highlight the importance of optimizing diagnostic test follow-up for younger veterans with IDA and hematochezia. By addressing these disparities and improving follow-up rates, it may be possible to enhance early age-onset colorectal cancer-related outcomes and reduce disparities based on sex, race, and ethnicity.

These findings also call for further research to better understand the reasons behind these disparities and to develop interventions that can improve the diagnostic follow-up process for veterans and other individuals at risk of colorectal cancer.

In conclusion, this study sheds light on a critical issue in colorectal cancer diagnosis and underscores the need for more equitable and timely diagnostic testing, especially among younger individuals with iron-deficiency anemia and hematochezia.

Source and credit: JAMA Network Open Journal

Posted on

Study Reveals Personalized Screening Ages for Colorectal Cancer Based on Genetic and Gender Factors

New research shows risk-adapted screening can vary by as much as 24 years for average-risk individuals without a family history of colorectal cancer (CRC).

A recent cohort study of 242,779 individuals with no prior family history of colorectal cancer (CRC) has unveiled the potential for personalized screening ages, demonstrating that risk-adapted starting ages can vary significantly based on sex and polygenic risk scores (PRS). The study employed a novel concept known as the “risk advancement period” (RAP) to determine how many years earlier or later individuals, particularly men compared to women, would reach comparable CRC risk levels. The results indicated that risk-adapted screening ages could differ by up to 24 years, even among individuals considered at average risk.

A new study, published in JAMA Network Open Journal, has addressed the question of how to translate risk variations in individuals without a family history of colorectal cancer (CRC) into personalized starting ages for screening. This research, which involved 242,779 participants with no previous CRC screening and no family history of the disease, demonstrated that risk-adapted starting ages can differ significantly based on sex and a polygenic risk score (PRS), which considers genetic factors. The study used the concept of the risk advancement period (RAP) to quantify the years by which men and individuals in different PRS groups would reach comparable risk levels compared to women and those in specific PRS deciles.

Key Findings:

  • The study included 242,779 participants aged 40 to 69 years, with a median age of 55 years and 55.7% women.
  • Over the course of the research, 2714 CRC cases were identified, with 758 CRC-related deaths.
  • Men had a 1.57-fold increased risk of CRC compared to women.
  • PRS played a significant role, with individuals in the lowest PRS deciles having half the risk and reaching equivalent risk levels 8 years older than those in the middle PRS deciles.
  • Individuals in the highest PRS decile had double the risk and reached equivalent risk levels 10 years younger.
  • RAP estimates revealed that men reached equivalent risk levels about 6 years earlier than women.
  • Risk-adapted screening ages could differ by as much as 24 years between men in the highest PRS decile and women in the lowest PRS decile.

Implications: The study highlights the potential for personalized screening ages based on individual risk factors. Current guidelines for CRC screening often do not consider these factors, leading to variations in screening recommendations in different countries. The findings suggest that using the risk advancement period concept could enable more precise and personalized screening recommendations based on factors like sex and genetic risk scores. However, challenges such as the cost of genetic testing and ethical considerations related to privacy and confidentiality must be addressed before implementing such an approach in routine clinical practice.

Conclusion: This study sheds light on the possibility of personalized screening for colorectal cancer, taking into account the unique risk profiles of individuals. The risk advancement period concept, which considers sex and polygenic risk scores, shows promise in providing tailored screening recommendations. However, further research and practical considerations are needed to determine the feasibility, cost-effectiveness, and ethical implications of implementing such an approach in healthcare settings.

Source: JAMA Network Open Journal